Interessante Biotechfirma - Supergen - 2.Amgen?

        Unternehmen wird von einem der Mitbegründer von Amgen geführt.








              [11/01/00 1:02 PM EST] SuperGen, Inc. (Nasdaq: SUPG)
              and SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), two
              biotech companies that RedChip Review™ covers, have
              suffered sharp declines in market value in recent weeks, yet the potential value of the drugs they are developing is as great as
              when their stocks were soaring. In my book that means they are much better buys now than they were before the current fire sale.

              SUPG’s stock, which had traded as high as $77 in early March,
              began to slide because of negative publicity. The shares dropped to under $30 in August after a couple of key people left. This
              happened in spite of the bundle of cash the company had raised earlier in the year to strengthen its balance sheet. Then Prudential
              downgraded the stock from “strong buy” to “hold,” suggesting
              that clinical trials of the company’s lead pancreatic cancer drug, Rubitecan, would be delayed about a year. The stock promptly
              fell another 30% or so to $20 a share. It lingered there, even though management denied that the trials would be late. Wall
              Street also has been unnerved by the negative signals sent by long-time SUPG investor and board member Larry Ellison.
              Ellison, who also is chairman and CEO of Oracle Corporation
              (Nasdaq: ORCL), has steadily been selling his SUPG shares.
              And the stock drifted lower, to $10.63 by mid-October, before
              edging back up to just under $13 yesterday.

              In some ways SUPG may be paying for its hubris. With a market
              cap under $500 million, SUPG is a small company, yet many of
              its top managers have a large-company mentality, which is to say they don’t seem to pay much attention to individual investors and
              analysts. Perhaps this is because Joe Rubinfeld, SUPG’s
              president and CEO, has been involved in large companies for
              most of his career.

              Rubinfeld has every reason to be haughty. After working as a
              research scientist with Schering-Plough Corp. (NYSE: SGP)
              and Colgate-Palmolive Company (NYSE:CL), he and three
              others founded Amgen, Inc. (Nasdaq: AMGN), one of today’s
              premier biotechnology companies. He went on to build the
              oncology department at Bristol-Myers (NYSE: BMY). If that
              were not enough, he also holds numerous patents and has
              published articles on a wide range of inventions and
              developments, including the 10-second developer for Polaroid
              film and the first commercial synthetic, biodegradable detergent. No doubt he now believes he can build SUPG into the Amgen
              opportunity he stepped away from just three years after he
              helped found it. And perhaps he can. But he might have to stoop to learning how to deal with small-cap investors if he is to
              succeed.

              Management personalities aside, Rubitecan has demonstrated
              clear effectiveness in prolonging the lives of pancreatic cancer victims. This is a terrible disease, and no therapy of any value
              currently exists. Moreover, should SUPG win FDA approval, we
              expect the drug to find favor among physicians in the treatment of other solid-tumor cancers. Thus the market could extend well
              beyond treatment of pancreatic cancer.

              While SUPG may have been too expensive early in the year, the
              pendulum has now swung too far in the other direction.
              Management’s quirks and the possible delay of clinical trials do not negate the potential value of Rubitecan. Risk-tolerant
              investors, however, have an opportunity to buy into SUPG at
              very reasonable prices. Consider that the book value of the
              company is over $5 per share, and cash is $3.70 of that. That
              makes the company’s $13 price look even better.              
Aus www.redchip.com



Schlusskurs heute 19,48$/+13%

Aktuelle Meldung vom 2.11.2000

Thursday November 2, 9:45 am Eastern Time

Press Release

SOURCE: SuperGen Inc.

SuperGen's Decitabine Achieved 100 Percent
Response Rate in Limited Clinical Study of Sickle Cell
Anemia Patients

Results of Phase I/II trial published in October issue of Blood

SAN RAMON, Calif., Nov. 2 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that its
anticancer compound decitabine generated a response in 100 percent of the patients tested in a Phase I/II clinical study
designed to establish safety and efficacy in the treatment of sickle cell anemia. These data were published in the October issue
of Blood, a preeminent hematology publication.

The study, headed by Dr. Mabel Koshy of the University of Illinois at Chicago, enrolled a total of eight patients: five of whom
had shown no response to Hydroxyurea (HU), the current standard of care, after one year of treatment; two of whom had a
moderate but unsustained response to HU; and, one patient who was not treated with HU. Each of the eight patients treated
with decitabine experienced elevated levels of fetal hemoglobin, which prevents 'sickle-shaped' cells from congregating,
allowing them to move freely throughout the body. (The clustering of such 'sickle cells' can result in severe pain, stroke, renal
failure, loss of sight, and substantial organ damage.)

After administration of decitabine, the five patients previously treated with HU experienced an average 35-fold increase of fetal
hemoglobin levels compared to levels during HU treatment. The two patients who responded briefly to HU experienced an
average fetal hemoglobin level increase of 52 percent with decitabine compared to treatment with HU. The one patient who
had not received HU treatment experienced more than a 50 percent increase in fetal hemoglobin levels. Side effects were
minimal, and the drug was well- tolerated. While HU has been shown to induce fetal hemoglobin, it is not effective in all
patients.

``We are quite pleased at the dramatic results of the Phase I/II study, given the seriousness and lack of effective treatment for
sickle cell anemia,'' said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``Plans for additional clinical
studies of decitabine as a treatment for sickle cell anemia are underway.

``The results of this study lend strong evidence to our belief that decitabine may become another platform technology for the
treatment of cancer,'' added Dr. Rubinfeld. ``In addition to sickle cell anemia, decitabine is in clinical studies for a variety of
solid tumors and hematological malignancies, including myelodysplastic syndrome, non-small cell lung cancer and chronic
myelogenous leukemia. The compound's unique mechanism of action - the hypomethylation of DNA - is a new area of keen
interest in not only sickle cell anemia, but has implications for the reactivation of tumor suppressor genes in cancer therapy.''

``The exciting data generated by decitabine underscores the breadth of the SuperGen portfolio, which includes four drugs that
will be in Phase III clinical studies in the near-term,'' stated Dr. Rubinfeld.

Sickle cell anemia is an inherited disorder of the red blood cells. Red blood cells carry oxygen to all parts of the body by using
a protein called fetal hemoglobin. Normal red blood cells contain only normal hemoglobin and are shaped like discs. These cells
are very flexible and move easily through small blood vessels. But in sickle cell anemia, the red blood cells contain sickle
hemoglobin, which causes them to change to a curved shape (sickle shape) after oxygen is released. 'Sickled' cells become
stuck and form plugs in small blood vessels. This blockage of blood flow can damage the tissue. Because there are blood
vessels in all parts of the body, damage can occur anywhere in the body.

Sickle cell anemia is most common among people whose ancestors come from Africa, the Middle East, the Mediterranean
basin, and India. In the United States, it affects primarily African Americans, more than 50,000 of whom have the disease,
according to the Center for Disease Control and Prevention. One in 12 African-Americans carries the sickle cell trait and most
sickle cell patients commonly die in their thirties and forties.

Based in San Ramon, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization
of products intended to treat life-threatening diseases, particularly cancer.

Statements relating to SuperGen's decitabine trials are 'forward-looking' statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve
certain risks and uncertainties associated with an emerging pharmaceutical company actively involved in clinical trials. Actual
results could differ materially from those projected in the 'forward-looking' statements as a result of failure to obtain the clinical
data necessary to support marketing approval of its products under development, unforeseen delays in clinical-trial
management, adverse FDA actions, as well as other risks discussed in SuperGen's reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, the report on Form 10-K for the fiscal year ended December 31, 1999,
and its report on Form 10-Q for the quarter ended June 30, 2000).

SOURCE: SuperGen Inc.

Gruß Dampf



 

SuperGen ist hauptsächlich in der Krebsforschung aktiv.
Der Kurs der Aktie ist von 77$ im Mai auf 13$ Mitte Oktober zurückgekommen. Dafür gab es mehrere Gründe:

1. Einige Topleute des Management verliesen die Firma, obwohl sich die finanzielle Lage des Unternehmens verbessert hat.
2. Ein Downgrade durch Prudential von Strong buy auf auf hold, da man davon ausging, dass sich die klinische Erprobung ihres wichtigsten Medikaments Rubitecan um ein Jahr hinauszögern würde - dies wird vom Unternehmen bestritten.
3.Larry Ellison, CEO von Oracle und Boardmember von SUPG verkaufte seine Anteile, die er lange gehalten hatte.

Laut Meinung des Autors liegt es aber hauptsächlich an der Überheblichkeit und unangemessenen Umgang mit Analysten und Investoren durch die Geschäftsleitung.

Der Präsident von SUPG Joe Rubinfeld war Mitberünder von Amgen, hatte vorher leitende Stellungen in der Forschung bei Schering und Colgate, baute die Krebsforschungabteilung bei Bristol-Myers (BMY) auf und hält persönlich wichtige Patente (10-Sekunden Entwickler von Polaroid, erstes biologisch abbaubares Waschmittel etc.). Nach drei Jahren hat er Amgen verlassen und versucht nun mit SUPG eine ähnliche Erfolgsgeschichte aufzubauen. Zuzutrauen ist es ihm, da mit Rubitecan ein sehr erfolgsversprechendes Medikament in der Krebsbehandlung entwickelt wurde.

Von den üblichen Risiken eines Invests in der Biotechnologie abgesehen, erscheint der Kurs z.Z. äußerst günstig.
Der Buchwert der Aktie beträgt alleine 5$ und der Cashbestand der Firma liegt bei 3,70$ pro Aktie.


So weit meine "freie" Übersetzung des obigen Artikels

Gruß Dampf



 

...& eine vielversprechende Pipeline in der Firmenschublade!

http://www.supergen.com/product/2_2.htm  

Hallo,

folgendes habe ich mal von www.trading-division.de kopiert:

Nicht mehr ganz aktuell, trotzdem interessant...

... (automatisch gekürzt) ...

www.trading-division.de

 

http://www.ragingbull.altavista.com/articles/tzavlakis/05-23-00.html

Leider auch auf englisch und etwas älter, deswegen einige Infos schon leicht überholt - trotzdem ganz interessant.

Gruß Dampf  

Friday August 11, 9:15 am Eastern Time

Press Release
SOURCE: SuperGen Inc.

SuperGen Reports Second Quarter Financial Results

Three-month revenue increases 118 percent; six-month revenue up 69 percent

Company now has cash and cash equivalents of $148 million on-hand

SAN RAMON, Calif., Aug. 11 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) today reported financial results for the second quarter ended June 30, 2000.

Revenue for the 2000 second quarter was $3,111,000, an increase of 118 percent, compared with revenue of $1,424,000 for the comparable period in 1999. Domestic sales of Nipent increased 136 percent in the 2000 second quarter, and 115 percent for the six months, compared to the same periods last year. The net loss for the 2000 second quarter was $7,908,000, or $0.24 per share, compared with a net loss of $5,299,000, or $0.25 per share, for the same period last year.

Revenue for the six months ended June 30, 2000 was $3,950,000, an increase of 69 percent, compared with revenue of $2,340,000 for the comparable period in 1999. The net loss for the six months ended June 30, 2000, was $15,447,000, or $0.51 per share. Net cash used for operations, however, was $13,117,000. For the six months ended June 30, 1999, the company reported a net loss of $10,166,000, or $0.48 per share. Net cash used for operations during that period was $9,335,000.

Research and development (R&D) expense increased 126 percent for the 2000 second quarter and 116 percent for the six months, compared to the same two periods last year. The increase in net loss for both the second quarter and the six months was mainly attributable to the substantial growth in R&D expense.

``With the increased R&D funding, we continue to accelerate our aggressive clinical program, including the Phase III clinical studies of rubitecan,'' said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``Such a process involves the accrual of patients at over 200 medical centers nationwide, as well as a substantial increase in the hiring of oncologists and other clinical professionals at the corporate level.

``Other products in clinical development include decitabine, Avicine(TM), lucanthone and Nipent, which is being studied for a variety of additional indications beyond its approved indication, hairy cell leukemia,'' added Dr. Rubinfeld.

``While the company's clinical programs continue to progress, we have taken numerous steps to strengthen our financial position,'' continued Dr. Rubinfeld. ``Since the beginning of this year, we have raised approximately $61 million through a secondary offering, $38 million through the redemption of warrants and received an up-front initial investment of $31 million from our partnership with Abbott Laboratories, for a total of roughly $130 million. All told, we have approximately $148 million in cash and cash equivalents on- hand.''

Other significant announcements during the course of the second quarter included: the presentation of data showing Nipent's effectiveness against Graft-Versus-Host Disease (GVHD); the presentation of data demonstrating rubitecan's activity in lung and prostate cancer studies; the acquisition of sales and marketing rights to Avicine from AVI BioPharma; the issuance of a patent protecting the company's proprietary Extra(TM) technology platform; the awarding of a grant from the National Cancer Institute (NCI) to develop 'IPdR' as an oral radiation-sensitizing drug; the entering into a Cooperative Research and Development Agreement (CRADA) with the NCI for decitabine; the acquisition of lucanthone from Dr. Robert Bases at the Albert Einstein College of Medicine in New York City; and, the presentation of data demonstrating rubitecan's activity in pancreatic cancer patients who have failed prior treatments, as well as rubitecan's activity in a number of solid tumors.

Based in San Ramon, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer.

This press release contains 'forward-looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements, including those regarding the clinical development of rubitecan, decitabine, lucanthone and Avicine, involve certain risks and uncertainties associated with an emerging pharmaceutical company. Actual results could differ materially from those projected in the 'forward-looking' statements as a result of failure to obtain the clinical data necessary to support marketing approval for rubitecan, decitabine, lucanthone and Avicine in the U.S., as well as other risk factors discussed in SuperGen's reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, the report on Form 10-K for the year ended December 31, 1999, and the report filed on Form 10-Q/A for the three months ended March 31, 2000).

   Consolidated financial statements to follow....

                               SUPERGEN INC.
                    CONSOLIDATED STATEMENT OF OPERATIONS
                  (in thousands, except per share amounts)
                                (unaudited)

                           Three months ended            Six Months Ended
                                June 30,                     June 30,
                           2000         1999             2000       1999
   Revenues:
    Net sales revenue      $2,861        $1,424       $3,556        $2,340
    Other revenue             250             -          394             -
     Total revenue          3,111         1,424        3,950         2,340

   Operating expenses:
    Cost of sales             650           484          774         1,192
    Research and
     development            8,300         3,675       14,648         6,795
    Selling, general
     and administrative     4,480         2,055        7,416         4,107
      Total operating
       expenses            13,430         6,214       22,838        12,094
   Loss from operations  (10,319)       (4,790)     (18,888)       (9,754)

   Interest income          2,411           143        3,441           283
   Amortization of loan
    commitment fee              -         (652)            -         (695)
   Net loss              $(7,908)      $(5,299)   $ (15,447)    $ (10,166)

   Basic net loss
    per share             $(0.24)       $(0.25)      $(0.51)       $(0.48)
   Weighted average
    shares used in
    basic net loss
    per share
    calculation            32,479        21,585       30,195        21,325



                        SELECTED BALANCE SHEET DATA
                               (in thousands)
                                (unaudited)


                                               June 30, 2000  June 30, 1999

   Cash, cash equivalents &
    marketable securities                          $148,344        $14,919

   Total assets                                    $175,534        $25,918

   Total stockholders' equity                      $166,988        $22,318


SOURCE: SuperGen Inc.  

Tuesday November 7, 9:45 am Eastern Time

Press Release

SOURCE: SuperGen Inc.

SuperGen's Pentostatin (Nipent(R)) Produced 'Durable
Complete Responses' in Ten-Year Follow-Up Study of
Patients Diagnosed with Hairy Cell Leukemia

83 Percent of Patients are Still Alive 11 to 14 Years Later

Results of study published in November issue of Blood

SAN RAMON, Calif., Nov. 7 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG; SUPGZ) announced today that its
anticancer compound pentostatin (Nipent®) produced 'durable complete responses' in patients diagnosed with hairy cell
leukemia, according to a long-term follow-up study. Data from this study were published in the November issue of Blood, a
preeminent hematology publication. Nipent is currently marketed by SuperGen for the treatment of hairy cell leukemia.

The study, headed by Dr. Ian Flynn at Johns Hopkins University, enrolled a total of 241 patients who were diagnosed with
hairy cell leukemia between December 1986 and September 1989. One hundred and fifty-four (154) patients were treated
with pentostatin (Nipent) as the initial therapy, and 87 patients failed interferon alpha as the initial therapy and were crossed
over to pentostatin (Nipent). The median follow-up time was 9.3 years. The objectives of the follow-up study were to evaluate
long-term survival, relapse-free survival, and incidence of subsequent malignancies.

Eighty-three (83) percent of patients treated with pentostatin are still alive 11-14 years after their first pentostatin treatment. The
five-year survival rate for 201 evaluable patients is 90 percent, and the ten-year survival rate is 81 percent. Patients younger
than 55 years of age had a ten- year survival rate of 93 percent, compared to a ten-year survival rate of 68 percent in patients
older than 55 years of age. While 40 of the 241 patients enrolled in the study have died, only two deaths were attributed to
hairy cell leukemia.

``These data from this long-term follow up trial confirm our belief that Nipent is an effective first-line treatment for hairy cell
leukemia,'' said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``It is clear that Nipent has had a
significant impact in the management of hairy cell leukemia, as the natural history of the disease has been enhanced.

``It is our intention to establish Nipent as a third technology platform, in addition to rubitecan and decitabine, for the treatment
of a variety of hematologic malignancies,'' added Dr. Rubinfeld.

Earlier this year, at a meeting sponsored by the American Society for Blood & Marrow Transplantation, data were presented
demonstrating Nipent's activity in the treatment of graft-versus-host disease (GVHD). Seven of the nine patients participating in
the study had Grade IV GVHD, and two had Grade III GVHD. All patients had failed high-dose steroids as their primary
GVHD treatment. Prior to receiving pentostatin (Nipent), many of the patients also had failed salvage therapy with
cyclosporine, FK-506, ATG, MMF, Daclitumab and Infliximab. The pentostatin (Nipent) therapy was well-tolerated. Four
patients achieved a complete response, and a partial response was observed in two patients, giving an overall response rate of
66 percent.

Based in San Ramon, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization
of products intended to treat life-threatening diseases, particularly cancer.

Statements relating to SuperGen's Nipent trials are ``forward-looking'' statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve
certain risks and uncertainties associated with an emerging pharmaceutical company actively involved in clinical trials. Actual
results could differ materially from those projected in the 'forward-looking' statements as a result of failure to obtain the clinical
data necessary to support marketing approval of its products under development, unforeseen delays in clinical-trial
management, adverse FDA actions, as well as other risks discussed in SuperGen's reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, the report on Form 10-K for the fiscal year ended December 31, 1999,
and its report on Form 10-Q for the quarter ended June 30, 2000).

Gruß Dampf


 

Wednesday November 8, 9:45 am Eastern Time

Press Release

SOURCE: SuperGen Inc.

SuperGen's decitabine "may play a significant role in
future therapy of cancers, both hematologic and
solid," says M.D. Anderson Cancer Center oncologist

Data reported today at 'XVIII Chemotherapy Foundation Symposium' sponsored by Mount Sinai
School of Medicine

SAN RAMON, Calif., Nov. 8 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that data
reported this morning at Mount Sinai School of Medicine's XVIII Chemotherapy Foundation Symposium by Hagop M.
Kantargian, M.D., Chairman of the Department of Leukemia, M. D. Anderson Cancer Center, Houston, will conclude that
``decitabine may play a significant role in future therapy of cancers, both hematologic and solid.''

First, Dr. Kantagian reported on three studies of decitabine to treat myelodysplastic syndrome (MDS) in 125 total patients with
an overall response rate of 49 percent. Also, Dr. Kantargian reported on a study using decitabine to treat chronic myelogenous
leukemia (CML) in a total of 81 patients with a response rate of 62 percent among patients in chronic phase of the disease.

Previously, SuperGen announced that decitabine generated a response in 100 percent of the patients tested in a Phase I/II
clinical study designed to establish safety and efficacy in the treatment of sickle cell anemia. These data were published in the
October issue of Blood.

Gruß Dampf

``These studies continue to give us great hope that decitabine is a platform technology for the treatment of cancer,'' said Dr.
Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``Our compound's unique mechanism of action - the
hypomethylation of DNA - is a groundbreaking area of significant interest in the reactivation of tumor suppressor genes in
cancer therapy. These exciting data associated with decitabine underscore the breadth of the SuperGen drug-portfolio, which
includes four compounds that will be in Phase III clinical trials soon,'' added Dr. Rubinfeld.  

halten sich bei dem umfeld mit +5,7% ausgesprochen tapfer.
nur schade, dass ich jetzt weg muss und erst den schlusskurs erfahren werde  

Da hat sich jemand ganz fett eingedeckt. Jetzt wird der Kurs bestimmt wieder abbröckeln - aber was solls, wenn man sich den Rest an der Nasdaq ansieht.

Gruß Dampf  

Bin erst vor wenigen Tagen auf Supergen aufmerksam geworden. Durch diesen Thread... Bin gestern leider nicht mit meinem Limit von 25 Euro bedient worden. Ich denke, daß ich am Montag nochmal eine Chance bekomme, speziell bei diesem Marktumfeld. Halte die Story für sehr aussichtsreich! Die o.g. Presseauszüge hören sich sehr vielversprechend an und zeigen, daß das Unternehmen auf dem richtigen Weg ist. Hoffentlich reißen sich die Oberen von Supergen zusammen und bringen die Medikamente gut durch die klinischen Prüfphasen. Mein persönliches Urteil: 4 Bangs (von 5 möglichen). Also ich werde zugreifen. Wer steigt mit ein?

Gruß

rocket  

Monday, November 13, 2000

                      SUPG misses by a penny
                      --9:36 am - By Michael Baron
                      SuperGen (SUPG: news, msgs) is sliding $1.98, or 9.2 percent, to $19.50, after the San Ramon,
                      Calif., pharmaceutical firm reported a wider-than-expected loss in the third quarter. SuperGen lost
                      $9.8 million, or 30 cents a share, in the latest three months, narrower than last year's loss of $18.2
                      million, or 78 cents a share, and a penny wider than First Call's average loss estimate. Revenue for
                      the quarter was $793,000, slightly higher than $736,000 last yea  

aber durchaus im Rahmen des allgemeinen Trends bei den Biotechs geblieben.
Wobei das Quartalsergebnis kaum ins Gewicht fällt, da SUPG erst ein Medikament vertreibt und damit Gewinne erzielt, dementsprechend Umsatz- und Ertragszahlen nicht sehr aussagekräftig sind. Inwieweit der Verlust auf gestiegene Kosten im Forschungsbereich zurückzuführen ist, was ja durchaus positiv zu sehen wäre, lässt sich aus der Kurzmeldung auch nicht ersehen.

Ich bin jedenfalls mit einer kleinen Position seit einer Woche dabei - bis jetzt +/- 0.

Gruß Dampf  

Bilanz ebenfalls +/- 0.

Langsam wird auch ABGX wieder interessant:

 

SuperGen Reports Third Quarter Financial Results

Nine-month revenue up 54 percent to $4.7 million

SAN RAMON, Calif., Nov. 10 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG; SUPGZ) today reported financial results
for the third quarter ended September 30, 2000.

Revenue for the 2000 third quarter was $793,000, compared with revenue of $736,000 for the comparable period in 1999.
The net loss for the 2000 third quarter was $9,893,000, or $0.30 per share, a decrease of 46 percent, compared with a net
loss of $18,214,000, or $0.78 per share, for the same period last year.

Revenue for the nine months ended September 30, 2000 was $4,743,000, an increase of 54 percent, compared with revenue
of $3,076,000 for the same period in 1999. The net loss for the nine months ended September 30, 2000, was $25,340,000,
or $0.81 per share. For the nine months ended September 30, 1999, the company reported a net loss of $28,380,000, or
$1.29 per share.

Included in the net losses for the three months and nine months ended September 30, 2000 and 1999 were one time non-cash
charges related to the acquisition of in-process research and development of $1,585,000 and $10,850,000, respectively.

Research and development (R&D) expense increased 102 percent for the 2000 third quarter and 111 percent for the nine
months, compared to the same two periods last year.

``The increase in R&D can be attributed to an extremely aggressive clinical research program,'' said Dr. Joseph Rubinfeld,
chairman and chief executive officer of SuperGen. ``We currently have over 25 different clinical trials underway in a variety of
compounds and indications. Looking forward, we will soon initiate three additional Phase III clinical studies for Nipent®,
Avicine(TM) and decitabine.

``Our multi-arm Phase III clinical study of rubitecan is the largest clinical trial ever undertaken for pancreatic cancer,'' added
Dr. Rubinfeld. ``We now have more than 1,400 patients enrolled in the study, and we expect that enrollment in one of the three
arms of the trial will be completed in the very near-term. Data from any of the three arms can independently be used in the filing
of a New Drug Application.''

Other significant announcements during the course of the third quarter included data presented at the Leukemia 2000
conference showing that the company's anticancer compound rubitecan has significant activity in several hematologic
malignancies, including chronic myeloid leukemia, chronic myelomonocytic leukemia and myelodysplastic syndrome;
discussions about the potential of Nipent in graft-versus-host disease and other hematologic malignancies at the Leukemia 2000
conference; and, the authorization by the board of directors for a repurchase program to buy back up to one million shares of
common stock.